Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $43.52 in the prior trading day, Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $43.44, down -0.18%. In other words, the price has decreased by -$0.18 from its previous closing price. On the day, 0.72 million shares were traded. XENE stock price reached its highest trading level at $43.86 during the session, while it also had its lowest trading level at $43.04.
Ratios:
Our goal is to gain a better understanding of XENE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.52 and its Current Ratio is at 12.52. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $55.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $67.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $67 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 05 ’25 when MORTIMER IAN sold 14,375 shares for $45.03 per share. The transaction valued at 647,306 led to the insider holds 16,830 shares of the business.
MORTIMER IAN sold 10,830 shares of XENE for $495,207 on Dec 08 ’25. The PRESIDENT & CEO now owns 6,000 shares after completing the transaction at $45.73 per share. On Dec 08 ’25, another insider, IAN MORTIMER, who serves as the Officer of the company, bought 10,830 shares for $45.73 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 3356826368 and an Enterprise Value of 2902885120. For the stock, the TTM Price-to-Sale (P/S) ratio is 447.58 while its Price-to-Book (P/B) ratio in mrq is 5.99. Its current Enterprise Value per Revenue stands at 387.051 whereas that against EBITDA is -8.584.
Stock Price History:
The Beta on a monthly basis for XENE is 0.98, which has changed by 0.10316861 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.60, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is 4.95%, while the 200-Day Moving Average is calculated to be 20.62%.
Shares Statistics:
The stock has traded on average 784.03K shares per day over the past 3-months and 796140 shares per day over the last 10 days, according to various share statistics. A total of 77.12M shares are outstanding, with a floating share count of 74.73M. Insiders hold about 3.30% of the company’s shares, while institutions hold 106.39% stake in the company. Shares short for XENE as of 1764288000 were 5889334 with a Short Ratio of 7.51, compared to 1761868800 on 5785686. Therefore, it implies a Short% of Shares Outstanding of 5889334 and a Short% of Float of 8.5.
Earnings Estimates
Investors are keenly observing as 13.0 analysts analyze and rate. The current performance of Xenon Pharmaceuticals Inc (XENE) in the stock market.The consensus estimate for the next quarter is -$1.13, with high estimates of -$0.95 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$4.12 and -$4.55 for the fiscal current year, implying an average EPS of -$4.27. EPS for the following year is -$4.57, with 15.0 analysts recommending between -$2.15 and -$5.33.
